Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 CAD | -.--% | -.--% | -.--% |
15/04 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
Sales 2021 | - | Sales 2022 | 0.29 0.4 24.47 | Capitalization | 11.48M 15.82M 958M |
---|---|---|---|---|---|
Net income 2021 | -4M -5.51M -334M | Net income 2022 | -3M -4.13M -250M | EV / Sales 2021 | - |
Net Debt 2021 | 75.05K 103K 6.26M | Net Debt 2022 | 1.15M 1.58M 95.87M | EV / Sales 2022 | 4,30,43,762 x |
P/E ratio 2021 |
-7.9
x | P/E ratio 2022 |
-3.02
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 86.26% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 20/16/20 | |
President | 56 | 20/16/20 | |
Chief Tech/Sci/R&D Officer | - | 15/20/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
President | 56 | 20/16/20 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 11/18/11 |
Vitor Fonseca
BRD | Director/Board Member | 71 | 11/18/11 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 142K | |
+39.33% | 6.11B | |
-18.38% | 4.35B | |
-9.17% | 3.18B | |
+3.98% | 3.16B | |
-3.41% | 2.51B | |
+48.74% | 1.98B | |
-4.82% | 1.74B | |
-1.24% | 1.63B | |
-8.96% | 1.6B |
- Stock Market
- Equities
- PILL Stock